$27 million to map 50 million human cells and uncover genetic fingerprints of disease
Illumina, a global genomics and human health company, has partnered with the Garvan Institute of Medical Research’s TenK10K project to help transform the treatment of complex diseases, starting with autoimmune diseases, with a joint investment of $27 million AUD.
The Garvan Institute plans to map 50 million human cells from 10,000 people to identify unique genomic fingerprints of autoimmune diseases, heart diseases and cancer, building on the early success of a clinical trial for Crohn’s disease.
Crohn’s disease affects more than 80,000 Australians. As with many autoimmune diseases, ...












